newsfilter
← Latest News
GlobeNewswire·

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient